#USA #Providence #EpiVax #Immunogenicity #AI-technology

EpiVax Unveils AI-Powered Innovations for Immunogenicity Risk Prediction

EpiVax, Inc. has recently announced the launch of groundbreaking AI-aided enhancements to its in silico platform, ISPRI™, aimed at accurately assessing the immunogenicity risks of biotherapeutics. This initiative is poised to significantly advance the field of computational immunology, building on the company’s notable legacy in the realm of cutting-edge biotherapeutic evaluation tools.

For over two decades, EpiVax has pioneered innovations in computational immunology, allowing researchers to effectively evaluate the potential immunogenic risks associated with biologics. The newly enhanced ISPRI™ includes advanced models like JanusMatrix™, adjusted tolerance-based immunogenicity scores, and enhanced predictions for anti-drug antibodies (ADAs), all designed to provide an even deeper insight into immunogenicity risks that may impact therapeutic efficacy.

Enhanced Features of ISPRI™

1. Updated JanusMatrix™

The improved JanusMatrix™ 2.1 applies advanced artificial intelligence techniques to refine predictive capabilities concerning immune tolerance. By incorporating data on human epitope cross-conservation, it offers a more precise characterization of therapeutic epitopes and their associated tolerance profiles.

2. JanusMatrix-Adjusted EpiMatrix Scores

Building upon JanusMatrix 2.1's capabilities, EpiVax has introduced a new immunogenicity scoring system that closely aligns with clinical outcomes. The JanusMatrix-Adjusted EpiMatrix (JAX) score integrates tolerance potential into EpiMatrix scores, enabling developers to obtain a clearer understanding of effector epitope density and a biologically informed perspective on sequence-derived immunogenicity risks across various therapeutic modalities.

3. Enhanced ADA Prediction Model

With the release of ADA 2.2, EpiVax has significantly improved its prediction model for anti-drug antibodies. This updated model merges epitope-based measurements with biophysical characteristics and specific action criteria to provide a comprehensive assessment of antibody immunogenicity risks. It has been trained using a diverse set of clinical monoclonal antibodies, enhancing its predictive accuracy in correlating predicted immunogenicity with clinical observations.

Importance of Enhanced Immunogenicity Predictions

These advanced features not only bolster EpiVax's status as a leader in immunoinformatics but also enhance the relevance and predictive capabilities of in silico immunogenicity assessments. The improvements align with FDA's recent initiatives promoting human-relevant New Approach Methodologies (NAMs), aiming to help sponsors identify potential immune liabilities efficiently. This is critical in safeguarding the development value and minimizing risks associated with novel therapeutic developments.

About EpiVax

EpiVax collaborates closely with developers in the biologics sector to help navigate immunogenicity risks throughout the lifecycle of their products. By leveraging extensive scientific expertise and leading in silico analysis techniques, they assist their partners in making informed decisions, mitigating risks, and optimizing resource use—all while ensuring compliance with regulatory standards and paving the way for safer and more effective therapies.

Conclusion

The launch of these AI-powered enhancements marks a significant milestone in the immunogenicity assessment field, heralding a new era of precision and reliability in biotherapeutic development. With EpiVax at the forefront of this technological evolution, the potential for improved patient outcomes and therapeutic safety is greater than ever.

Media Contact:
Sarah Moniz
Director of Business Development
Marketing
Email: [email protected]